Metropolitan Life Insurance CO Rigel Pharmaceuticals Inc Transaction History

Metropolitan Life Insurance CO

  • $281 Million
  • Q3 2024

Shares

59 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024
BUY
$1.12 - $1.57 $526 - $737
470 Added 12.01%
4,383 $6,000
Q4 2023

Feb 14, 2024
SELL
$0.72 - $1.56 $3,990 - $8,647
-5,543 Reduced 58.62%
3,913 $5,000
Q1 2023

May 15, 2023
SELL
$1.25 - $2.0 $1,631 - $2,610
-1,305 Reduced 12.13%
9,456 $12,000
Q4 2022

Jun 14, 2023
BUY
$0.67 - $11.9 $874 - $15,529
1,305 Added 13.8%
10,761 $16.1 Million
Q4 2022

Mar 30, 2023
BUY
$0.67 - $11.9 $140 - $2,487
209 Added 1.98%
10,761 $16,000
Q4 2022

Feb 15, 2023
BUY
$0.67 - $11.9 $140 - $2,487
209 Added 1.98%
10,761 $16,000
Q3 2022

Jun 14, 2023
BUY
$1.1 - $12.2 $1,205 - $13,371
1,096 Added 11.59%
10,552 $12.5 Million
Q3 2022

Mar 30, 2023
BUY
$1.1 - $12.2 $9,555 - $105,981
8,687 Added 465.79%
10,552 $11,000
Q3 2022

Nov 14, 2022
BUY
$1.1 - $12.2 $9,555 - $105,981
8,687 Added 465.79%
10,552 $12,000
Q2 2022

Jun 20, 2023
SELL
$0.67 - $3.19 $5,085 - $24,215
-7,591 Reduced 80.28%
1,865 $2,000
Q2 2022

Mar 30, 2023
SELL
$0.67 - $3.19 $6,610 - $31,472
-9,866 Reduced 84.1%
1,865 $2,000
Q2 2022

Aug 11, 2022
SELL
$0.67 - $3.19 $6,610 - $31,472
-9,866 Reduced 84.1%
1,865 $2,000
Q1 2022

Jun 20, 2023
BUY
$2.22 - $3.45 $5,050 - $7,848
2,275 Added 24.06%
11,731 $35,000
Q1 2022

Mar 30, 2023
SELL
$2.22 - $3.45 $79,695 - $123,851
-35,899 Reduced 75.37%
11,731 $35,000
Q1 2022

May 12, 2022
SELL
$2.22 - $3.45 $79,695 - $123,851
-35,899 Reduced 75.37%
11,731 $35,000
Q4 2021

Jun 21, 2023
BUY
$2.36 - $3.57 $90,090 - $136,281
38,174 Added 403.7%
47,630 $126,000
Q4 2021

Mar 30, 2023
BUY
$2.36 - $3.57 $9,720 - $14,704
4,119 Added 9.47%
47,630 $126,000
Q4 2021

Feb 15, 2022
BUY
$2.36 - $3.57 $9,720 - $14,704
4,119 Added 9.47%
47,630 $126,000
Q3 2021

Jun 21, 2023
BUY
$3.5 - $4.5 $119,192 - $153,247
34,055 Added 360.14%
43,511 $157,000
Q3 2021

Mar 30, 2023
BUY
$3.5 - $4.5 $22,893 - $29,434
6,541 Added 17.69%
43,511 $157,000
Q3 2021

Nov 15, 2021
BUY
$3.5 - $4.5 $22,893 - $29,434
6,541 Added 17.69%
43,511 $158,000
Q2 2021

Jun 21, 2023
BUY
$3.09 - $4.54 $85,018 - $124,913
27,514 Added 290.97%
36,970 $160,000
Q2 2021

Mar 30, 2023
SELL
$3.09 - $4.54 $40,027 - $58,811
-12,954 Reduced 25.95%
36,970 $160,000
Q2 2021

Aug 16, 2021
BUY
$3.09 - $4.54 $114,082 - $167,616
36,920 Added 73840.0%
36,970 $160,000
Q1 2021

Jun 26, 2023
BUY
$3.35 - $4.93 $135,567 - $199,507
40,468 Added 427.96%
49,924 $171 Million
Q1 2021

Mar 30, 2023
BUY
$3.35 - $4.93 $6,137 - $9,031
1,832 Added 3.81%
49,924 $170,000
Q1 2021

May 14, 2021
SELL
$3.35 - $4.93 $160,940 - $236,847
-48,042 Reduced 99.9%
50 $171,000
Q4 2020

Jun 22, 2023
BUY
$2.35 - $3.74 $90,794 - $144,498
38,636 Added 408.59%
48,092 $168,000
Q4 2020

Mar 30, 2023
SELL
$2.35 - $3.74 $2,930 - $4,663
-1,247 Reduced 2.53%
48,092 $168,000
Q4 2020

Feb 16, 2021
SELL
$2.35 - $3.74 $2,930 - $4,663
-1,247 Reduced 2.53%
48,092 $168,000
Q3 2020

Jun 26, 2023
BUY
$1.78 - $4.13 $70,991 - $164,716
39,883 Added 421.77%
49,339 $118,000
Q3 2020

Mar 30, 2023
SELL
$1.78 - $4.13 $14,494 - $33,630
-8,143 Reduced 14.17%
49,339 $118,000
Q3 2020

Nov 13, 2020
SELL
$1.78 - $4.13 $14,494 - $33,630
-8,143 Reduced 14.17%
49,339 $118,000
Q2 2020

Jun 26, 2023
BUY
$1.41 - $2.05 $67,716 - $98,453
48,026 Added 507.89%
57,482 $105,000
Q2 2020

Mar 30, 2023
BUY
$1.41 - $2.05 $146 - $213
104 Added 0.18%
57,482 $105,000
Q2 2020

Aug 14, 2020
BUY
$1.41 - $2.05 $146 - $213
104 Added 0.18%
57,482 $105,000
Q1 2020

Jul 12, 2023
BUY
$1.27 - $3.0 $60,860 - $143,766
47,922 Added 506.79%
57,378 $89,000
Q1 2020

Mar 30, 2023
SELL
$1.27 - $3.0 $2,813 - $6,645
-2,215 Reduced 3.72%
57,378 $89,000
Q1 2020

May 15, 2020
SELL
$1.27 - $3.0 $2,813 - $6,645
-2,215 Reduced 3.72%
57,378 $90,000
Q4 2019

Jul 12, 2023
BUY
$1.6 - $2.43 $80,219 - $121,832
50,137 Added 530.21%
59,593 $127,000
Q4 2019

Mar 30, 2023
BUY
$1.6 - $2.43 $26,211 - $39,808
16,382 Added 37.91%
59,593 $127,000
Q4 2019

Feb 14, 2020
BUY
$1.6 - $2.43 $26,211 - $39,808
16,382 Added 37.91%
59,593 $128,000
Q3 2019

Jul 12, 2023
BUY
$1.63 - $2.62 $55,020 - $88,438
33,755 Added 356.97%
43,211 $80,000
Q3 2019

Mar 30, 2023
SELL
$1.63 - $2.62 $14,435 - $23,202
-8,856 Reduced 17.01%
43,211 $80,000
Q3 2019

Nov 14, 2019
SELL
$1.63 - $2.62 $14,435 - $23,202
-8,856 Reduced 17.01%
43,211 $81,000
Q2 2019

Jul 12, 2023
BUY
$2.02 - $2.61 $86,074 - $111,214
42,611 Added 450.62%
52,067 $135,000
Q1 2019

Jul 13, 2023
BUY
$2.0 - $2.65 $85,222 - $112,919
42,611 Added 450.62%
52,067 $133,000
Q1 2019

Mar 30, 2023
BUY
$2.0 - $2.65 $82,612 - $109,460
41,306 Added 383.85%
52,067 $133,000
Q1 2019

May 16, 2019
BUY
$2.0 - $2.65 $91,188 - $120,824
45,594 Added 704.37%
52,067 $133,000
Q1 2019

May 15, 2019
SELL
$2.0 - $2.65 $86,798 - $115,007
-43,399 Reduced 87.02%
6,473 $163,000
Q4 2018

Jul 13, 2023
BUY
$2.08 - $3.36 $84,065 - $135,797
40,416 Added 427.41%
49,872 $114,000
Q4 2018

Feb 14, 2019
BUY
$2.08 - $3.36 $80,724 - $130,401
38,810 Added 350.84%
49,872 $115,000
Q3 2018

Jul 13, 2023
BUY
$2.6 - $3.59 $105,081 - $145,093
40,416 Added 427.41%
49,872 $160 Million
Q3 2018

Nov 14, 2018
SELL
$2.6 - $3.59 $100,906 - $139,327
-38,810 Reduced 77.82%
11,062 $36,000
Q2 2018

Aug 15, 2018
BUY
$2.83 - $4.11 $11,113 - $16,139
3,927 Added 8.55%
49,872 $0
Q1 2018

May 15, 2018
BUY
$3.54 - $4.54 $43,396 - $55,655
12,259 Added 36.39%
45,945 $0
Q4 2017

Feb 15, 2018
SELL
$3.23 - $4.3 $413,885 - $550,993
-128,138 Reduced 79.18%
33,686 $131,000
Q3 2017

Nov 14, 2017
BUY
$2.18 - $2.57 $149,410 - $176,140
68,537 Added 73.47%
161,824 $411,000
Q2 2017

Aug 14, 2017
BUY
N/A
93,287
93,287 $255,000

Others Institutions Holding RIGL

# of Institutions
8
Shares Held
334K
Call Options Held
0
Put Options Held
0
View Full List

About RIGEL PHARMACEUTICALS INC

RIGL Quotes by TradingView
  • Ticker RIGL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 172,836,000
  • Market Cap $2.96B
  • Description
  • Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is ...
More about RIGL
Track This Portfolio

Track Metropolitan Life Insurance CO Portfolio

Follow Metropolitan Life Insurance CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Metropolitan Life Insurance CO, based on Form 13F filings with the SEC.

News

Stay updated on Metropolitan Life Insurance CO with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email